Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New bowel cancer test could save lives through early detection

Innovation Research

A new screening test, funded by NIHR Oxford BRC, is being hailed the most efficient way to indicate risk of colorectal cancer.

First stage UK research, published today, shows that an advanced computer algorithm technology can successfully indicate levels of risk by analysing previous blood test results in patients’ existing medical records.

The paper, ‘Evaluation of a prediction model for colorectal cancer: retrospective analysis of 2.5 million patient records’, is published today in the journal Cancer Medicine.

Advances in algorithm technology – a mathematical analysis of data – have led to the ability to search ultra-rapidly through existing NHS records to determine whether a patient is at risk of colorectal cancer.

This has the potential to save lives through early detection as well as reducing the need for unnecessary costly and invasive tests.

The algorithm, established in Tel Aviv and shown to work on the Israeli population, has now been trialled in the very different UK population.

This radically different approach has been tested over the past two years by Oxford University and funded by the NIHR Oxford Biomedical Research Centre.

Read more (Oxford Biomedical Research Centre website)

Similar stories

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.